ABT-888 |
VELIPARIB |
PARP-1 INHIBITOR ABT-888 |
ABT 888 |
2-[(R)-2-METHYLPYRROLIDIN-2-YL]-1H-BENZIMIDAZOLE-4-CARBOXAMIDE |
(2R)-2-(7-CARBAMOYL-1H-BENZIMIDAZOL-2-YL)-2-METHYLPYRROLIDINIUM |
2-((2R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE |
pubchem.compound:11960529 |
drugbank:07232 |
chembl:CHEMBL506871 |
chemidplus:912444-00-9 |
Pharmaceutical Developer | Active Biochem |
Source Reported Drug Name(s) | Veliparib/ABT-888 |
Drug Class | PARP Inhibitor |
Drug Class | Small molecule inhibitor |
Drug Categories | poly(adp-ribose) polymerase inhibitors |
Drug Categories | heterocyclic compounds, fused-ring |
inhibitor (inhibitory) |
Mechanism of Interaction | PARP 1, 2 and 3 inhibitor |
Direct Interaction | yes |
Notes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | PARP 1, 2 and 3 inhibitor |
Reported Cancer Type | Prostate |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | PARP 1, 2 and 3 inhibitor |
n/a |
n/a |
Indication/Tumor Type | stomach cancer |
Response Type | sensitive |
Approval Status | Preclinical - Cell line xenograft |
n/a |
combination therapy | AZD6482 + Veliparib |
Indication/Tumor Type | triple-receptor negative breast cancer |
Response Type | sensitive |
VELIPARIB | DrugBank Drug Name |
912444-00-9 | CAS Number |
CHEMBL506871 | ChEMBL ID |
Drug Type | small molecule |
Drug Groups | investigational |
Drug Categories | antineoplastic agents |
ABT-888 | Development Name |
VELIPARIB | Generic Name |
Drug Class | Small molecule inhibitor |
2-((R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide | PubChem Drug Name |
11960529 | PubChem Drug ID |
Veliparib | Drug Trade Name |
Drug Class | PARP Inhibitor |
Source Reported Drug Name(s) | Veliparib/ABT-888 |
Pharmaceutical Developer | Active Biochem |
D0Q7UD | TTD Drug ID |
VELIPARIB | Primary Drug Name |
VELIPARIB | Drug Generic Name |
ABT-888 | Drug Synonym |